BR9912066A - Uso de um ingrediente ativo; método de tratamento de restenose; e; composição farmacêutica - Google Patents

Uso de um ingrediente ativo; método de tratamento de restenose; e; composição farmacêutica

Info

Publication number
BR9912066A
BR9912066A BR9912066-6A BR9912066A BR9912066A BR 9912066 A BR9912066 A BR 9912066A BR 9912066 A BR9912066 A BR 9912066A BR 9912066 A BR9912066 A BR 9912066A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
active ingredient
treatment method
restenosis treatment
restenosis
Prior art date
Application number
BR9912066-6A
Other languages
English (en)
Inventor
Gershon Golomb
Haim Daneberg
Original Assignee
Yissum Res Dev Co
Hadasit Med Res Service
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yissum Res Dev Co, Hadasit Med Res Service filed Critical Yissum Res Dev Co
Publication of BR9912066A publication Critical patent/BR9912066A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Mechanical Treatment Of Semiconductor (AREA)
  • Saccharide Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

"USO DE UM INGREDIENTE ATIVO, MéTODO DE TRATAMENTO DE RESTENOSE, E, COMPOSIçãO FARMACêUTICA" Bisfosfonatos (BP), pirofosfato (PP), um complexo de BP ou PP, um polímero de BP ou PP ou um éster ou sal farmacêuticamente aceitável dos mesmos, são usados para prevenção ou tratamento de restenose vascular.
BR9912066-6A 1998-07-14 1999-07-14 Uso de um ingrediente ativo; método de tratamento de restenose; e; composição farmacêutica BR9912066A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IL12533698A IL125336A0 (en) 1998-07-14 1998-07-14 Compositions for inhibition and treatment of restinosis
PCT/IL1999/000387 WO2000003677A2 (en) 1998-07-14 1999-07-14 Use of bisphosphonates in the treatment of vascular restenosis

Publications (1)

Publication Number Publication Date
BR9912066A true BR9912066A (pt) 2001-04-10

Family

ID=11071743

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912066-6A BR9912066A (pt) 1998-07-14 1999-07-14 Uso de um ingrediente ativo; método de tratamento de restenose; e; composição farmacêutica

Country Status (17)

Country Link
US (1) US6719998B1 (pt)
EP (2) EP1468691B1 (pt)
JP (4) JP4663116B2 (pt)
KR (1) KR20010074711A (pt)
CN (1) CN1321090A (pt)
AT (2) ATE471149T1 (pt)
AU (1) AU758882B2 (pt)
BR (1) BR9912066A (pt)
CA (1) CA2337175C (pt)
DE (2) DE69915834T2 (pt)
EE (1) EE200100025A (pt)
ES (2) ES2347553T3 (pt)
IL (3) IL125336A0 (pt)
NO (1) NO20010224L (pt)
PL (1) PL345782A1 (pt)
SK (1) SK472001A3 (pt)
WO (1) WO2000003677A2 (pt)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
US7008645B2 (en) * 1998-07-14 2006-03-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method of inhibiting restenosis using bisphosphonates
PT1178810E (pt) * 1999-05-21 2005-08-31 Novartis Ag Utilizacao de acidos bisfosfonicos para o tratamento de angiogenese
EP1267888A4 (en) * 2000-01-04 2005-12-28 Univ California USE OF LOW-DOSEED BISPHOSPHONATES FOR PREVENTING THE CALIBRATION OF HEART AND ARTERIES
JP4290985B2 (ja) * 2001-02-16 2009-07-08 アボット ラボラトリーズ バスキュラー エンタープライゼズ リミテッド Ｆｋ５０６を用いたインプラント
US6656506B1 (en) * 2001-05-09 2003-12-02 Advanced Cardiovascular Systems, Inc. Microparticle coated medical device
EP1553957A1 (en) * 2002-10-15 2005-07-20 Novartis AG Bisphosphonates for the treatment of atherosclerosis and devices comprising them
US8034361B2 (en) * 2002-11-12 2011-10-11 Advanced Cardiovascular Systems, Inc. Stent coatings incorporating nanoparticles
AU2004253527B2 (en) * 2003-06-27 2010-04-08 Zuli Holdings Ltd. Method of treating acute coronary syndromes
US10517883B2 (en) * 2003-06-27 2019-12-31 Zuli Holdings Ltd. Method of treating acute myocardial infarction
US20060051407A1 (en) * 2003-06-27 2006-03-09 Yoram Richter Method of treating ischemia-reperfusion injury
US20050153937A1 (en) * 2003-11-07 2005-07-14 Gershon Golomb Desensitization of compliment activation using monocyte/macrophage inhibitory compounds
CN100364544C (zh) * 2004-07-21 2008-01-30 上海第二医科大学附属瑞金医院 一种携带二氯亚甲基二膦酸的明胶微粒及制备方法
WO2008128056A1 (en) 2004-10-08 2008-10-23 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods with enhanced potency for multiple targets including fpps, ggpps, and dpps
WO2006039721A2 (en) 2004-10-08 2006-04-13 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods for bone resorption diseases, cancer, bone pain, immune disorders, and infectious diseases
ES2366654T3 (es) * 2005-02-17 2011-10-24 HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT CO., LTD. Biofosfonatos para tratar la endometriosis.
US8158153B2 (en) * 2005-03-17 2012-04-17 Alkermes Pharma Ireland Limited Nanoparticulate bisphosphonate compositions
AU2007226964B2 (en) 2006-03-17 2012-03-22 The Board Of Trustees Of The University Of Illinois Bisphosphonate compounds and methods
US20080181928A1 (en) * 2006-12-22 2008-07-31 Miv Therapeutics, Inc. Coatings for implantable medical devices for liposome delivery
US8802184B2 (en) 2007-05-30 2014-08-12 Abbott Cardiovascular Systems Inc. Medical devices containing biobeneficial particles
EP2211926A2 (en) * 2007-10-10 2010-08-04 Miv Therapeutics Inc. Lipid coatings for implantable medical devices
US20090148491A1 (en) * 2007-12-05 2009-06-11 Abbott Cardiovascular Systems Inc. Dual-Targeted Drug Carriers
EP2255199A1 (en) * 2008-02-19 2010-12-01 Jovesis Inc. Microparticle compositions to modify cancer promoting cells
CA2730085A1 (en) * 2008-07-09 2010-01-14 Board Of Regents Of The University Of Nebraska Functional micelles for hard tissue targeted delivery of chemicals
WO2011163389A2 (en) * 2010-06-25 2011-12-29 The Trustees Of Columbia University In The City Of New York Method for inducing fat loss in mammals
GB201200868D0 (en) * 2012-01-19 2012-02-29 Depuy Int Ltd Bone filler composition
US9993427B2 (en) 2013-03-14 2018-06-12 Biorest Ltd. Liposome formulation and manufacture
CN106456775A (zh) 2014-05-16 2017-02-22 生物休眠有限公司 双膦酸盐作为hiv/aids辅助治疗的用途
WO2018025809A1 (ja) * 2016-08-01 2018-02-08 株式会社カネカ カルシプロテインパーティクルの吸着材、および吸着除去システムとその利用方法
CN106361701B (zh) * 2016-08-31 2019-08-27 上海交通大学 一种脂质体药物载体及其制备方法和应用
FR3068233A1 (fr) * 2017-07-03 2019-01-04 Omnium De Revalorisation Industrielle Odri Dispositif medical intra-arteriel et applications
JP6613290B2 (ja) 2017-11-28 2019-11-27 株式会社Ｓｕｂａｒｕ 運転アドバイス装置及び運転アドバイス方法

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4067971A (en) 1976-05-13 1978-01-10 The Procter & Gamble Company Therapeutic composition
US4216211A (en) 1977-10-31 1980-08-05 The Procter & Gamble Company Therapeutic composition
WO1988000289A1 (en) 1986-07-09 1988-01-14 Engine Technology Limited Piston rings
CH675422A5 (pt) * 1988-03-31 1990-09-28 Symphar Sa
IL91362A0 (en) 1989-08-20 1990-03-19 Yissum Res Dev Co Bisphosphonates,process for preparing them and pharmaceutical compositions containing them
US5196409A (en) 1989-08-20 1993-03-23 Yissum, Research Development Company Of The Hebrew University Of Jerusalem Bisphosphonates, pharmaceutical compositions, and process for the treatment of irregularities in calcium metabolism
PH27186A (en) 1989-09-07 1993-04-16 Ciba Geigy Ag Double-coated granules of disodium pamidronate
CA2042159A1 (en) 1990-05-31 1991-12-01 Miguel A. Ondetti Method for preventing onset of restenosis after angioplasty employing an ace inhibitor
WO1993009790A1 (en) * 1991-11-11 1993-05-27 The Trustees Of The University Of Pennsylvania Methods of inhibiting restenosis
US5358941A (en) 1992-12-02 1994-10-25 Merck & Co., Inc. Dry mix formulation for bisphosphonic acids with lactose
FI92465C (fi) 1993-04-14 1994-11-25 Risto Tapani Lehtinen Menetelmä endo-osteaalisten materiaalien käsittelemiseksi
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
US5457113A (en) * 1993-10-15 1995-10-10 Eli Lilly And Company Methods for inhibiting vascular smooth muscle cell proliferation and restinosis
JPH10511957A (ja) * 1995-01-05 1998-11-17 ザ ボード オブ リージェンツ オブ ザ ユニヴァーシティ オブ ミシガン 表面改質ナノ微粒子並びにその製造及び使用方法
US5652227A (en) 1995-01-30 1997-07-29 Teronen; Olli Pekka Inhibition of the degradation of connective tissue matrix protein components in mammals
US5741514A (en) * 1995-08-31 1998-04-21 Yissum Research Development Company Of The Hebrew University Of Jerusalem Method for reducing serum lipoprotein(a) concentration
CZ297979B6 (cs) * 1996-03-12 2007-05-16 Pg-Txl Company, L. P. Kompozice obsahující protinádorové lécivo konjugované s ve vode rozpustným polymerem, její pouzití pro výrobu léciva a implantovatelná lékarská pomucka
WO1997043437A2 (en) * 1996-05-15 1997-11-20 The University Of Sheffield Isopentenyl pyrophosphate isomerase (ipi) and/or prenyl transferase inhibitors
KR100192215B1 (ko) 1996-09-03 1999-06-15 강재헌 3-아미노-1-히드록시프로판-1,1-디포스폰산의 제조방법
CA2277273C (en) * 1997-01-17 2008-03-25 Merck & Co., Inc. Integrin antagonists
US5760030A (en) 1997-06-30 1998-06-02 Eli Lilly And Company Benzothiophene compounds and methods of use
US5932580A (en) 1997-12-01 1999-08-03 Yissum Research And Development Company Of The Hebrew University Of Jerusalem PDGF receptor kinase inhibitory compounds their preparation and compositions
EP1051511A1 (en) * 1998-01-29 2000-11-15 Merck & Co., Inc. Methods of identifying modulators of kinases responsive to stress
IL125336A0 (en) * 1998-07-14 1999-03-12 Yissum Res Dev Co Compositions for inhibition and treatment of restinosis
EP0998932A1 (de) 1998-10-09 2000-05-10 Boehringer Mannheim Gmbh Feste pharmazeutische Darreichungsform enthaltend Diphosphonsäure oder deren Salze und Verfahren zu ihrer Herstellung
US5932563A (en) 1998-10-23 1999-08-03 Ohio State Research Foundation Methods for treating spinal cord injury
ATE238315T1 (de) 1998-12-10 2003-05-15 Aesgen Inc Verfahren zur herstellung von dinatriumpamidronat
CA2370769A1 (en) 1999-04-22 2000-11-02 Hydromed Sciences A Division Of Gp Strategies Corporation Controlled delivery of bisphosphonates

Also Published As

Publication number Publication date
IL125336A0 (en) 1999-03-12
JP6088619B2 (ja) 2017-03-01
EP1468691A1 (en) 2004-10-20
CA2337175A1 (en) 2000-01-27
AU758882B2 (en) 2003-04-03
US6719998B1 (en) 2004-04-13
IL142172A0 (en) 2002-03-10
PL345782A1 (en) 2002-01-02
SK472001A3 (en) 2001-09-11
JP5498342B2 (ja) 2014-05-21
JP2013256524A (ja) 2013-12-26
WO2000003677A2 (en) 2000-01-27
EP1094820A2 (en) 2001-05-02
DE69915834D1 (de) 2004-04-29
NO20010224L (no) 2001-03-09
ATE471149T1 (de) 2010-07-15
CA2337175C (en) 2009-03-31
EP1094820B1 (en) 2004-03-24
JP2011037871A (ja) 2011-02-24
JP4663116B2 (ja) 2011-03-30
ATE262338T1 (de) 2004-04-15
NO20010224D0 (no) 2001-01-12
AU4646299A (en) 2000-02-07
IL142172A (en) 2007-07-24
CN1321090A (zh) 2001-11-07
ES2219028T3 (es) 2004-11-16
JP2016041724A (ja) 2016-03-31
KR20010074711A (ko) 2001-08-09
DE69942510D1 (de) 2010-07-29
ES2347553T3 (es) 2010-11-02
EP1468691B1 (en) 2010-06-16
JP5903081B2 (ja) 2016-04-13
WO2000003677A3 (en) 2000-05-04
EE200100025A (et) 2002-06-17
DE69915834T2 (de) 2005-03-24
JP2002520345A (ja) 2002-07-09

Similar Documents

Publication Publication Date Title
BR9912066A (pt) Uso de um ingrediente ativo; método de tratamento de restenose; e; composição farmacêutica
TR200101103T2 (tr) CGMP PDE-İnhibitörü içeren kontrollu serbest bırakılan farmasötik formülasyonlar
ATE286384T1 (de) Formulierung mit verzögerter freisetzung enthaltend kollagen und glykosaminoglykan
DK0804166T3 (da) Formulering med kontrolleret frigivelse (Albuterol)
HUP9802999A2 (hu) N-propargil-1-amino-indánt tartalmazó gyógyszerkészítmény
MY118151A (en) Pharmaceutical formulations containing voriconazole.
HUP0203028A2 (hu) Tolterodint tartalmazó gyógyszerkészítmény és alkalmazása
HRP20000494B1 (en) Pharmaceutically active morpholinol
ES2094539T3 (es) Preparacion farmaceutica y procedimiento para su preparacion.
EP1112758A3 (en) Laser beam treatment apparatus
AU2711295A (en) Combination treatment for inhibiting bone loss
WO1999016416A3 (de) Beschichtete medizinische implantate, verfahren zu ihrer herstellung und ihre verwendung zur restenoseprophylaxe
AU3868997A (en) Pharmaceutical composition containing osteogenesis-promoting substance and a polyethylene glycol
DE60042972D1 (de) Trimetazidine enthaltendes Arzneimittel mit verzögerter Wirkstoffabgabe und Verfahren zur Herstellung
PT885014E (pt) Composicoes farmaceuticas contendo polimeros orto ester tamponados
AU2773597A (en) Pharmaceutical compositions for the sustained release of insoluble active principles
PT1017681E (pt) Derivados de hidrazono-benzazuleno composicoes farmaceuticas e intermediarios
CA2385867A1 (en) Sustained release form comprising alpha-lipoic acid or derivatives thereof
MX9709453A (es) Composicion farmaceutica oral de compuestos de piperidinoalcanol en forma de solucion.
AP2001002369A0 (en) Pharmaceutical complex.
SE9902742D0 (sv) New pharmaceutical formultion
HUP0003885A2 (hu) Készítmény pangásos szívelégtelenség kezelésére
AU7568500A (en) Laser probe for medical treatment
ES2097181T3 (es) Composicion antidepresiva a base de nicotinamida-adenina-dinucleotido.
WO1998038985A3 (en) Use of carvedilol for the manufacture of a medicament for preventive and therapeutic treatment of inflammatory diseases

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A, 6A, 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1911 DE 21/08/2007.